| 主权项 |
1. A method of detecting the presence of a polymorphism in the PSMD14, LRP1B, or TMEFF2 gene and administering a treatment to a human subject, the method comprising:
(a) obtaining a genomic sample from a human subject having or at risk of developing SZ; (b) detecting the haplotype tagged by the “A” allele of rs9713, the haplotype tagged by the “C” allele of rs874295, or the haplotype tagged by the “C” allele of rs3738883 in the genomic sample; (c) identifying the subject having the haplotype tagged by the “A” allele of rs9713, the haplotype tagged by the “C” allele of rs874295, or the haplotype tagged by the “C” allele of rs3738883 in the genomic sample as likely to have an improved response to risperidone as compared to control subject; and (d) administering a treatment comprising risperidone to the subject with the haplotype tagged by the “A” allele of rs9713, the haplotype tagged by the “C” allele of rs874295, or the haplotype tagged by the “C” allele of rs3738883. |
